UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2014

Commission File Number: 001-16174

Teva Pharmaceutical Industries Ltd.
———————————————————————————————————
(Translation of registrant’s name into English)
 
Israel
———————————————————————————————————
(Jurisdiction of incorporation or organization)
 
5 Basel Street, P.O. Box 3190
Petach Tikva 4951033 Israel
———————————————————————————————————
(Address of principal executive office)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:  [x] Form 20-F    [ ] Form 40-F
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  [ ]
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  [ ]
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:  [ ] Yes    [x] No
 
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):    n/a 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
    Teva Pharmaceutical Industries Ltd.
     
Date: 10/06/2014 By: Eyal Desheh
  Name:  Eyal Desheh
  Title: Group EVP & CFO
     
EXHIBIT INDEX

Exhibit No.   Description
 
99.1   Teva to Report Third Quarter 2014 Financial Results on October 30, 2014
     
Exhibit  EX-99.1

Teva to Report Third Quarter 2014 Financial Results on October 30, 2014

Jerusalem, October 6, 2014 - Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its third quarter 2014 financial results on Thursday,
October 30, 2014 at 7:00 a.m. ET.

Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its third quarter 2014 results and overall business environment. A Question & Answer session will follow this discussion.

In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States 1-877-391-1148; Canada 1-866-992-3017 International +44(0) 1452-580733; passcode: 13650976. For a list of other international toll-free numbers, click here.

A live webcast of the call will also be available on Teva’s website at: www.tevapharm.com. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on the Company’s website. The replay can also be accessed until December 11, 2014, 8:00 a.m. ET by calling United States 1-866-247-4222; Canada 1-866-878-9237 or International +44 (0) 1452-550000; passcode: 13650976#.

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world’s leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in approximately 60 countries. Teva’s Specialty Medicines businesses focus on CNS, respiratory, oncology, pain, and women’s health therapeutic areas as well as biologics. Teva currently employs approximately 45,000 people around the world and reached $20.3 billion in net revenues in 2013.